Enhanced tumour-associated CD163 expression by immunohistochemistry (IHC) was associated with poor survival in a small study (65), while a larger study (n=335) found no association between CD66b(+) neutrophils and CD163(+) macrophages and survival in lung cancer patients (66). This evidence concerns the gene CD163 and lung carcinoma.